MDGL · Madrigal Pharmaceuticals reported Q3 2026 Rezdiffra net sales of…

Madrigal Pharmaceuticals reported Q3 2026 Rezdiffra net sales of $431.3M, a 50% YoY increase, and achieved its first profitable quarter with net income of $55.4M ($1.83 diluted EPS) versus a $114.2M loss a year ago. The company also announced a new Phase 3 MAESTRO-CSPH trial for compensated MASH cirrhosis (F4c) expected to start in H1 2027.

• Q3 2026 Rezdiffra net sales $431.3M, up 50% YoY from $287.3M
• First profitable quarter: net income $55.4M ($1.83 diluted EPS) vs net loss $114.2M ($4.01 loss per share) in Q3 2025
• Year-to-date Rezdiffra net sales $1.1B, achieving blockbuster status
• Over 55,850 patients on Rezdiffra as of Sept. 30, 2026, nearly double Q3 2025